Pubblicazioni

  1. Pacifico S, Albanese V, Illuminati D, Marzola E, Fabbri M, Ferrari F, Holanda VAD, Sturaro C, Malfacini D, Ruzza C, Trapella C, Preti D, Lo Cascio E, Arcovito A, Della Longa S, Marangoni M, Fattori D, Nassini R, Calò G, Guerrini R. (2021) Novel Mixed NOP/Opioid Receptor Peptide Agonists. J Med Chem. 64(10):6656-6669.
  2. Costanzini A, Ruzza C*, Neto JA, Sturaro C, Malfacini D, Sternini C, De Giorgio R, Calò G. (2021) Pharmacological characterization of naloxegol: In vitro and in vivo studies. Eur J Pharmacol. 903:174132.
  3. Reinscheid RK, Ruzza C. (2021) Pharmacology, Physiology and Genetics of the Neuropeptide S System. Pharmaceuticals (Basel). 14(5):401.
  4. Gavioli EC, Holanda VAD, Calo G, Ruzza C. (2021) Nociceptin/orphanin FQ receptor system blockade as an innovative strategy for increasing resilience to stress. Peptides. 141:170548.
  5. Neto JA, Ruzza C*, Sturaro C, Malfacini D, Pacifico S, Zaveri NT, Calò G. (2021) Functional selectivity does not predict antinociceptive/locomotor impairing potencies of NOP receptor agonists. Frontiers in Neuroscience. 15:657153.
  6. Albanese V#, Ruzza C#, Marzola E, Bernardi T, Fabbri M, Fantinati A, Trapella C, Reinscheid RK, Ferrari F, Sturaro C, Calo G, Amendola G, Cosconati S, Pacifico S, Guerrini R, Preti D. (2021) Structure-Activity Relationship Studies on Oxazolo[3,4-a]Pyrazine Derivatives Leading to the Discovery of a Novel Neuropeptide S Receptor Antagonist With Potent In Vivo Activity. Journal of Medicinal Chemistry. 64(7):4089-4108.
  7. Holanda VAD, Oliveira MC, Da Silva Junior ED, Calo' G, Ruzza C, Gavioli EC. (2020) Blockade of nociceptin/orphanin FQ signaling facilitates an active copying strategy due to acute and repeated stressful stimuli in mice. Neurobiology of Stress. 13:100255.
  8. Pacifico S, Ferrari F, Albanese V, Marzola E, Neto JA, Ruzza C, Calò G, Preti D, Guerrini R. (2020) Biased Agonism at Nociceptin/Orphanin FQ Receptors: A Structure Activity Study on N/OFQ(1-13)-NH2. Journal of Medicinal Chemistry. 63(19):10782-10795.
  9. Azevedo Neto J, Costanzini A, De Giorgio R, Lambert DG, Ruzza C*, Calò G. (2020) Biased versus Partial Agonism in the Search for Safer Opioid Analgesics. Molecules. 25(17):3870.
  10. Asth L, Tiago PRF, Costa LRF, Holanda VAD, Pacifico S, Zaveri NT, Calo' G, Ruzza C, Gavioli EC. (2020) Effects of non-peptide nociceptin/orphanin FQ receptor ligands on methylphenidate-induced hyperactivity in mice: Implications for bipolar disorders. Neuropeptides. 82:102059.
  11. Silva AI, Holanda VAD, Azevedo Neto JG, Silva Junior ED, Soares-Rachetti VP, Calo G, Ruzza C, Gavioli EC. (2020) Blockade of NOP receptor modulates anxiety-related behaviors in mice exposed to inescapable stress. Psychopharmacology (Berl). 237(6):1633-1642
  12. Ferrari F, Rizzo S, Ruzza C*, Calo G. (2020) Detailed In Vitro Pharmacological Characterization of the Clinically Viable Nociceptin/Orphanin FQ Peptide Receptor Antagonist BTRX-246040. Journal of Pharmacology and Experimental Therapeutics. 373(1):34-43
  13. Wtorek K, Adamska-Bartłomiejczyk A, Piekielna-Ciesielska J, Ferrari F, Ruzza C, Kluczyk A, Piasecka-Zelga J, Calo' G, Janecka A. (2019) Synthesis and Pharmacological Evaluation of Hybrids Targeting Opioid and Neurokinin Receptors. Molecules, 24(24):4460.
  14. Holanda VAD, Pacifico S, Azevedo Neto J, Finetti L, Lobão-Soares B, Calo G, Gavioli EC, Ruzza C. (2019) Modulation of the NOP receptor signaling affects resilience to acute stress. Journal of Psychopharmacology, 33(12), 1540-1549
  15. Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA; CGTP Collaborators. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. (2019) British Journal of Pharmacology. 176 Suppl 1(Suppl 1):S21-S141.
  16. Pacifico S, Albanese V, Illuminati D, Fantinati A, Marzola E, Ferrari F, Neto JA, Sturaro C, Ruzza C, Calò G, Preti D, Guerrini R. (2019) Tetrabranched Hetero-Conjugated Peptides as Bifunctional Agonists of the NOP and Mu Opioid Receptors. Bioconjugate Chemistry. 30(9):2444-2451
  17. Holanda VAD, Oliveira MC, Souza LS, Lobão-Soares B, André E, Da Silva Junior ED, Guerrini R, Calo G, Ruzza C, Gavioli EC. (2019) Dopamine D 1 and D 2 Receptors Mediate Neuropeptide S-induced Antinociception in the Mouse Formalin Test. European Journal of Pharmacology 859:172557
  18. Ruzza C, Holanda VA, Gavioli EC, Trapella C, Calo G (2018) NOP agonist action of cebranopadol counteracts its liability to promote physical dependence. Peptides. 112:101-105
  19. Ruzza C*, Ferrari F, Guerrini R, Marzola E, Preti D, Reinscheid RK, Calo' G (2018). Pharmacological profile of the neuropeptide S receptor: Dynamic mass redistribution studies. Pharmacology Research & Perspectives. e00445.
  20. Silva EF, Silva AI, Asth L, Souza LS, Zaveri NT, Guerrini R, Calo' G, Ruzza C, Gavioli EC (2019). Nociceptin/orphanin FQ receptor agonists increase aggressiveness in the mouse resident-intruder test. Behavioural Brain Research. 356, pp. 120-126
  21. Holanda VAD, Santos WB, Asth L, Guerrini R, Calo' G, Ruzza C, Gavioli EC. (2018). NOP agonists prevent the antidepressant-like effects of nortriptyline and fluoxetine but not R-ketamine. Psychopharmacology (Berl). 235(11), pp. 3093-3102
  22. Calo' G, Rizzi A, Ruzza C, Ferrari F, Pacifico S, Gavioli EC., Salvadori S, Guerrini, R. (2018). Peptide welding technology - a simple strategy for generating innovative ligands for G protein coupled receptors. Peptides. 99, pp. 195-204
  23. Rizzi A, Ruzza C, Bianco S, Trapella C, Calo' G (2017). Antinociceptive action of NOP and opioid receptor agonists in the mouse orofacial formalin test. Peptides. 94, pp. 71-77
  24. Alexander SP, Kelly E, Marrion NV, Peters JA, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Buneman OP, Cidlowski JA, Christopoulos A, Davenport AP, Fabbro D, Spedding M, Striessnig J, Davies JA; CGTP Collaborators. (2017) THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview. British Journal of Pharmacology. 174 Suppl 1(Suppl Suppl 1):S1-S16.
  25. Ruzza C, Calò G, Di Maro S, Pacifico S, Trapella C, Salvadori S, Preti D, Guerrini R. (2017) Neuropeptide S receptor ligands: a patent review (2005-2016). Expert Opinion on Therapeutic Patents. 27(3), pp. 347-362
  26. Cerlesi MC, Ding H, Bird MF, Kiguchi N, Ferrari F, Malfacini D, Rizzi A, Ruzza C, Lambert DG, Ko MC, Calo G, Guerrini R (2017). Pharmacological studies on the NOP and opioid receptor agonist PWT2-[Dmt1]N/OFQ(1-13). European Journal of Pharmacology. 794, pp. 115-126
  27. Rizzi A, Cerlesi MC, Ruzza C, Malfacini D, Ferrari F, Bianco S, Costa T, Guerrini R, Trapella C, Calo' G. (2016) Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin/orphanin FQ and opioid receptor agonist. Pharmacology Research & Perspectives. 4(4): e00247.
  28. Asth L, Ruzza C*, Malfacini D, Medeiros I, Guerrini R, Zaveri NT, Gavioli EC, Calo' G. (2016) Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic- versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands. Neuropharmacology. 105, pp. 434-442.
  29. Ferrari F, Cerlesi MC, Malfacini D, Asth L, Gavioli EC, Journigan BV, Kamakolanu UG, Meyer ME, Yasuda D, Polgar WE, Rizzi A, Guerrini R, Ruzza C, Zaveri NT, Calo G. (2016) In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations. European Journal of Pharmacology. 793, pp. 1-13.
  30. Rizzi A, Sukhtankar DD, Ding H, Hayashida K, Ruzza C, Guerrini R, Calò G, Ko MC. (2015) Spinal antinociceptive effects of the novel NOP receptor agonist PWT2-nociceptin/orphanin FQ in mice and monkeys. British Journal of Pharmacology. 172(14), pp. 3661-3670
  31. Ruzza C, Rizzi A, Malfacini D, Molinari S, Giuliano C, Lovati E, Pietra C, Calo' G. (2015) In vitro and in vivo pharmacological characterization of Pronetupitant, a prodrug of the neurokinin 1 receptor antagonist Netupitant. Peptides. 69, pp. 26-32
  32. Ruzza C*, Asth L, Guerrini R, Trapella C, Gavioli EC. (2015) Neuropeptide S reduces mouse aggressiveness in the resident/intruder test through selective activation of the neuropeptide S receptor. Neuropharmacology. 97, pp. 1-6
  33. Medeiros IU, Ruzza C, Asth L, Guerrini R, Romão PR, Gavioli EC, Calo G. (2015) Blockade of nociceptin/orphanin FQ receptor signaling reverses LPS-induced depressive-like behavior in mice. Peptides. 72, pp. 95-103
  34. Ruzza C, Rizzi A, Malfacini D, Pulga A, Pacifico S, Salvadori S, Trapella C, Reinscheid RK, Calo’ G, and Guerrini R (2015). In vitro and in vivo pharmacological characterization of a neuropeptide S tetrabranched derivative. Pharmacology Research & Perspectives. 3(1), pp. 1-10.
  35. Ruzza C, Del Zoppo L, Malfacini D, Pela’ M, Trapella C, Grieco P, Salvadori S, Calo’ G, and Guerrini R (2014). [D-Pen(p-tBuBzl)5]NPS, a novel ligand for the neuropeptide S receptor – structure activity and pharmacological studies. Medicinal chemistry research. 23(7), pp. 3503-3509
  36. Pelà M, Del Zoppo L, Allegri L, Marzola E, Trapella C, Ruzza C, Calo’ G, Perissutti E, Frecentese F, Salvadori S, Guerrini R. (2014). Racemic synthesis and solid phase peptide synthesis application of the chimeric Valine/Leucine derivative 2-amino-3,3,4-trimethyl-pentanoic acid. Pharmazie. 69(7), pp. 496-499
  37. Rizzi A, Malfacini D, Cerlesi MC, Ruzza C, Marzola E, Bird M., Rowbotham, DJ, Salvadori S, Guerrini R, Lambert DG, and Calo’ G. (2014) In vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives. British Journal of Pharmacology. 71(17), pp. 4138-4153
  38. Ruzza C, Rizzi A, Malfacini D, Cerlesi MC, Ferrari F, Marzola E, Ambrosio C, Gro’ C, Salvadori S, Costa T, Calo’ G, and Guerrini R. (2014). Pharmacological characterization of tachykinin tetrabranched derivatives. British Journal of Pharmacology. 171(17), pp. 4125-4137
  39. Camarda V, Ruzza C*, Rizzi A, Trapella C, Guerrini R, Reinscheid RK, Calo’ G. (2013) In vitro and in vivo pharmacological characterization of the novel neuropeptide S receptor ligands QA1 and PI1. Peptides. 48, pp. 27-35
  40. Pulga A, Ruzza C, Rizzi A, Guerrini R, Calo’ G. (2012) Anxiolytic- and panicolytic-like effects of Neuropeptide S in the mouse elevated T-maze. European Journal of Neuroscience 36(11), pp. 3531-3537
  41. Ruzza C*, Pulga A, Rizzi A, Marzola G, Guerrini R, Calo’ G. (2012) Behavioral phenotypic characterization of CD-1 mice lacking the neuropeptide S receptor. Neuropharmacology. 62(5-6), pp. 1999-2009
  42. Ruzza C, Rizzi A, Camarda V, Pulga A, Marzola G, Filaferro M, Novi C, Ruggieri V, Marzola E, Vitale G, Salvadori S, Guerrini R, Calo' G. (2012) [tBu-D-Gly5]NPS, a pure and potent antagonist of the neuropeptide S receptor: in vitro and in vivo studies. Peptides. 34(2), pp. 404-411.
  43. Trapella C, Pela M, Del Zoppo L, Calo G, Camarda V, Ruzza C, Cavazzini A, Costa V, Bertolasi V, Reinscheid RK, Salvadori S, Guerrini R. (2011) Synthesis and Separation of the Enantiomers of the Neuropeptide S Receptor Antagonist (9R/S)-3-Oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxyli Acid 4-Fluoro-benzylamide (SHA 68). Journal of Medicinal Chemistry. 54(8), pp. 2738-2744
  44. Ruzza C, Rizzi A, Trapella C, Pela' M, Camarda V, Ruggieri V, Filaferro M, Cifani C, Reinscheid RK, Vitale G, Ciccocioppo R, Salvadori S, Guerrini R, Calo' G. (2010) Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68. Peptides. 31(5), pp. 915-925.
  45. Guerrini R, Camarda V, Trapella C, Caló G, Rizzi A, Ruzza C, Fiorini S, Marzola E, Reinscheid RK, Regoli D, Salvatori S. (2009) Further studies at neuropeptide s position 5: discovery of novel neuropeptide S receptor antagonists. Journal of Medicinal Chemistry. 52(13), pp. 4068-4071
  46. Camarda V, Rizzi A, Ruzza C, Zucchini S, Marzola G, Marzola E, Guerrini R, Salvadori S, Reinscheid RK, Regoli D, Calo’ G. (2009) In vitro and in vivo pharmacological characterization of the neuropeptide S receptor antagonist [D-Cys(tBu)5]NPS. Journal of Pharmacology and Experimental Therapeutics. 328(2), pp. 549-555
  47. Guerrini R, Camarda V, Trapella C, Calò G, Rizzi A, Ruzza C, Fiorini S, Marzola E, Reinscheid RK, Regoli D, Salvadori S (2009). Synthesis and Biological Activity of Human Neuropeptide S Analogues Modified in Position 5: Identification of Potent and Pure Neuropeptide S Receptor Antagonists. Journal of Medicinal Chemistry. 52(2), pp. 524-529
  48. Camarda V, Trapella C, Calo' G, Guerrini R, Rizzi A, Ruzza C, Fiorini S, Marzola E, Reinscheid RK, Regoli D, Salvadori S. (2008) Structure-activity study at positions 3 and 4 of human neuropeptide S. Bioorg Med Chem. 16(19):8841-5.
  49. Rizzi A, Vergura R, Marzola G, Ruzza C, Guerrini R, Salvadori S, Regoli D, Calo’ G. (2008) Neuropeptides S is a stimulatory anxiolytic – a behavioral study in mice. British Journal of Pharmacology. 154(2), pp. 471-479
  50. Camarda V, Trapella C, Calo' G, Guerrini R, Rizzi A, Ruzza C, Fiorini S, Marzola E, Reinscheid RK, Regoli D, Salvadori S. (2008) Synthesis and biological activity of human neuropeptide S analogues modified in position 2. Journal of Medicinal Chemistry. 51(3), pp. 655-658

* autore corrispondente

# questi due autori hanno contribuito in maniera equivalente